Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine

Antiviral Therapy

Volumn 18, Issue 5, 2013, Pages 671-679

  Lo, Angeline Oi Shan ^a   Wong, Vincent Wai Sun ^a   Wong, Grace Lai Hung ^a   Chan, Hoi Yun ^a   Cheung, Christina Man Tung ^a   Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; RISK FACTORS; THYMIDINE; TREATMENT OUTCOME;

EID: 84888156508     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2526     Document Type: Article

References (26)

1. Chan HL, Jia JD. Chronic hepatitis B in Asia - new insights from the past decade. J Gastroenterol Hepatol 2011;26 Suppl 1:131-137.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
3. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-S181.
4. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Metaanalysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008;28:1067-1077.
5. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006;26:153-161.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2009;50:661-662.
7. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
8. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: 1 2012 update. Hepatol Int 2012;6:531-561.
9. Chan HL. Antiviral therapy for chronic hepatitis B: the challenges of Hong Kong. J Hepatol 2009;51:1088-1090.
10. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-754.
11. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
12. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
13. Tsoi KK, Lui YY, Wong VW, Chan HL. Cost-effectiveness analysis of anti-viral treatment strategies based on the roadmap model in chronic hepatitis B virus (HBV) infection. Hepatol Int. 2009;3:105.
14. Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Rev Anti Infect Ther 2009;7:259-268.
15. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-897.
16. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-1444.
17. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
18. Tenney DL, Rose RE, Baldick CL, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
19. Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002;68:182-187.
20. Piratvisuth T, Komolmit P, Tanwandee T, et al. 2-year results of telbivudine (LDT) roadmap study verify the optimal efficacy and safety results in HBeAg positive chronic hepatitis B (CHB) patients. Hepatol Int 2012;56 Suppl: S214.
21. Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000;31:1318-1326.
22. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507.
23. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance mechanisms, detection and interpretation. J Hepatol 2006;44:593-606.
24. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos (t) ide analogues. Gastroenterology 2009;137:1593-1608.
25. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747-755.
26. Wong VW, Wong GL, Tse CH, et al. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci 2012;57:221-231.